Recent Investment Analysts’ Ratings Updates for REGENXBIO (RGNX)

REGENXBIO (NASDAQ: RGNX) has recently received a number of price target changes and ratings updates:

• 6/24/2026 – REGENXBIO had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
• 6/22/2026 – REGENXBIO had its price target raised by Leerink Partners from $17.00 to $18.00. They now have an “outperform” rating on the stock.
• 6/22/2026 – REGENXBIO had its price target raised by Robert W. Baird from $27.00 to $32.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – REGENXBIO had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 6/5/2026 – REGENXBIO had its price target lowered by HC Wainwright from $30.00 to $26.00. They now have a “buy” rating on the stock.
• 5/15/2026 – REGENXBIO was given a new $16.00 price target by Morgan Stanley.
• 5/15/2026 – REGENXBIO had its price target lowered by Barclays PLC from $37.00 to $12.00. They now have an “overweight” rating on the stock.
• 5/15/2026 – REGENXBIO had its price target lowered by Bank of America Corporation from $25.00 to $14.00. They now have a “buy” rating on the stock.

Insider Activity at REGENXBIO

In related news, insider Steve Pakola sold 15,309 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the transaction, the insider directly owned 232,617 shares of the company’s stock, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.22% of the company’s stock.

Get REGENXBIO Inc alerts:

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

Featured Stories

• Five stocks we like better than REGENXBIO
• Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
• AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
• Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
• Xcel Energy Stock Offers Stability as Electricity Demand Builds

Receive News & Ratings for REGENXBIO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc and related companies with MarketBeat.com's FREE daily email newsletter.